EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mid-to Long-term Outcomes After Single Radiofrequency Ablation of Nontoxic and Toxic Thyroid Nodules

Harald Dobnig iD, Karin Amrein iD

The Journal of Clinical Endocrinology & Metabolism · 22.04.2026 · 111 (5) · 1397-1407

DOI: 10.1210/clinem/dgaf611 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 04.11.2025. Verfasst von Harald Dobnig und 1 weiteren Autor:innen. Beteiligte Einrichtung: Thyroid Practice and Clinic for Radiofrequency Ablation and Minimally Invasive Interventions, Kumberg 8062, Austria. Hauptthemen laut MEDLINE: Thyroid Nodule, Radiofrequency Ablation, Neoplasm Recurrence, Local, Adenoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the mid- to long-term recurrence rates after a single radiofrequency ablation (RFA) of benign thyroid adenomas.

Design

Retrospective review of data collected in a standardized prospective database.

Setting

Single-center thyroid clinic in Austria.

Participants

Eight hundred ninety-six consecutive patients with either nontoxic nodules (n = 765) or toxic adenomas (n = 131).

Intervention

Mono- or bipolar RFA under local anesthesia. Main Outcome Measures Recurrence defined as increase in nodule size after RFA treatment by ≥50% from its smallest volume (nontoxic adenomas) or relapse of hyperthyroidism (toxic adenomas).

Results

Follow-up periods of 3 years or more were available for 437 nontoxic and 58 toxic adenomas. The median baseline volume was 10.1 mL [interquartile range (IQR) 5.5-20] for nontoxic and 7.2 mL (IQR 4.2-14.3) for toxic nodules. Solid or predominantly solid nodules comprised 81% and 93%, respectively. After 1, 3, and 5 years, the average nodule volume decreased by 79%, 82%, and 86% for nontoxic and by 84%, 88%, and 89% for toxic nodules, remaining stable afterwards. In 54 patients (7.1%) with nontoxic nodules, regrowth occurred, with a cumulative incidence rate of 17.3% over a maximum of 8 years. Among 15 patients (11.5%) with toxic adenomas, recurrence of hyperthyroidism was observed over 7 years (21.6% cumulative incidence). Fourteen of these patients became euthyroid after low-dose radioiodine treatment (n = 11) or a second RFA (n = 3). Documented complications included 2.3% moderate and 0.3% severe cases.

Conclusion

In our cohort, a single RFA treatment resulted in favorable mid- to long-term outcomes in 83% of nontoxic and 78% of toxic adenoma patients, with an acceptable complication rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NoduleRadiofrequency AblationNeoplasm Recurrence, LocalAdenomaThyroid NeoplasmsHumansFemaleMaleMiddle AgedRetrospective StudiesAdultTreatment OutcomeFollow-Up StudiesAgedHyperthyroidism

Stichwörter der Autor:innen

RFAautonomous adenomathermoablationthyroid nodules

Autor:innen und Institutionen

  • Thyroid Practice and Clinic for Radiofrequency Ablation and Minimally Invasive Interventions, Kumberg 8062, Austria.
  • Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8010, Austria.

ORCID-Profile: Harald Dobnig, Karin Amrein

Zitieren

APA

Dobnig, H., & Amrein, K. (2026). Mid-to Long-term Outcomes After Single Radiofrequency Ablation of Nontoxic and Toxic Thyroid Nodules. The Journal of Clinical Endocrinology & Metabolism, 111(5), 1397-1407. https://doi.org/10.1210/clinem/dgaf611

Vancouver

Dobnig H, Amrein K. Mid-to Long-term Outcomes After Single Radiofrequency Ablation of Nontoxic and Toxic Thyroid Nodules. The Journal of Clinical Endocrinology & Metabolism. 2026;111(5):1397-1407. doi:10.1210/clinem/dgaf611

BibTeX
@article{Dobnig2026,
  author = {Dobnig, Harald and Amrein, Karin},
  title = {Mid-to Long-term Outcomes After Single Radiofrequency Ablation of Nontoxic and Toxic Thyroid Nodules},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {5},
  pages = {1397--1407},
  doi = {10.1210/clinem/dgaf611}
}
Kostenlos starten →